Assenagon Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.53M Buy
353,044
+120,097
+52% +$1.09M ﹤0.01% 728
2026
Q1
$2.22M Sell
232,947
-126,633
-35% -$983K ﹤0.01% 763
2025
Q4
$2.8M Sell
359,580
-2,733,012
-88% -$19.8M ﹤0.01% 785
2025
Q3
$23.5M Sell
3,092,592
-528,045
-15% -$4.4M 0.03% 339
2025
Q2
$32.4M Buy
3,620,637
+3,606,566
+25,631% +$33.6M 0.05% 285
2025
Q1
$106K Hold
14,071
﹤0.01% 1130
2024
Q4
$106K Hold
14,071
﹤0.01% 1293
2024
Q3
$107K Sell
14,071
-50,836
-78% -$386K ﹤0.01% 1346
2024
Q2
$401K Sell
64,907
-321,978
-83% -$1.78M ﹤0.01% 1269
2024
Q1
$1.97M Sell
386,885
-142,534
-27% -$802K 0.01% 904
2023
Q4
$3.17M Sell
529,419
-580,485
-52% -$3.36M 0.01% 768
2023
Q3
$7.86M Sell
1,109,904
-4,223,010
-79% -$30.3M 0.03% 446
2023
Q2
$37.5M Buy
5,332,914
+365,077
+7% +$2.93M 0.15% 134
2023
Q1
$41.4M Buy
4,967,837
+2,377,445
+92% +$22.9M 0.16% 129
2022
Q4
$29.7M Sell
2,590,392
-25,765
-1% -$321K 0.12% 194
2022
Q3
$33M Sell
2,616,157
-561,714
-18% -$7.23M 0.14% 156
2022
Q2
$33.6M Buy
3,177,871
+3,107,027
+4,386% +$32.1M 0.14% 158
2022
Q1
$1.15M Buy
70,844
+57,608
+435% +$924K ﹤0.01% 1019
2021
Q4
$183K Sell
13,236
-53,891
-80% -$713K ﹤0.01% 1381
2021
Q3
$965K Sell
67,127
-687,905
-91% -$10.8M ﹤0.01% 915
2021
Q2
$11.9M Buy
755,032
+710,563
+1,598% +$9.65M 0.05% 307
2021
Q1
$452K Buy
+44,469
New +$459K ﹤0.01% 1042
2020
Q3
Sell
-303,400
Closed -$1.45M 1130
2020
Q2
$1.45M Buy
+303,400
New +$1.21M 0.01% 690
2020
Q1
Sell
-74,744
Closed -$258K 799
2019
Q4
$258K Buy
+74,744
New +$188K ﹤0.01% 715

Other funds holding BCRX